Introduction
============

Breast cancer is the most common cancer and the main cause of cancer mortality in women. The etiology towards to this disease is poorly understood, some risk factors including familial history of the disease, age of menarche and of menopause, diet, reproductive history, high estrogen exposure as well as genetic factors may contribute to its development \[[@B1],[@B2]\]. Studies suggest that the effect determined by low-penetrance genes, may provide a plausible explanation for BC susceptibility. Polymorphisms in genes are associated with a risk or protection against the disease. 5,10-methylenetetrahydrofolate reductase (*MTHFR*) is one important genes located at 1p36.3 \[[@B3]\]. *MTHFR Ala222Val* polymorphism has become the most commonly studied one, which has been considered to influence the enzyme activity of *MTHFR*\[[@B4]\]. The MTHFR 222Val/Val (homozygote) genotype results in 30% enzyme activity in vitro compared with the Ala/Ala wild-type \[[@B5]\]. Numerous epidemiological studies have evaluated the association between the *MTHFR Ala222Val* polymorphisms and BC risk. However, these studies have yielded conflicting results, partially because of the possible small effect of the polymorphism on BC risk and the relatively small sample size in each of published studies. The aim of this study is to derive a more precise estimation of these associations by performing this meta-analysis.

Materials and methods
=====================

Literature search
-----------------

All studies that examined the association between the *MFTHR Ala222Val* polymorphism and BC were identified. A comprehensive search was conducted through researching MEDLINE, EMBASE, PubMed, Web of Science, China Biomedical Literature database (CBM) and China National Knowledge Infrastructure (CNKI) databases before August 2012. The search strategy included the combination of "breast cancer," "breast neoplasm," "methylene-tetrahydrofolate reductase," "*MTHFR*," "Ala222Val", "rs1801133", "variant," and "polymorphism." References of the retrieved articles were also screened. Non-familial case--control studies were eligible if they determined the distribution for this polymorphism in unrelated patients with breast cancer and in a concurrent control group of healthy subjects using molecular methods for genotyping. Of the studies with the same or overlapping data by the same investigators, we selected the most recent ones with the most subjects. We evaluated all associated publications to retrieve the most eligible literatures. The reference lists of reviews and retrieved articles were hand searched at the same time. We did not include abstracts or unpublished reports. When overlapping data of the same patient population were included in more than one publication, only the most recent or complete study was used in this meta-analysis.

Inclusion and exclusion criteria
--------------------------------

The following inclusion criteria were used to select literatures for the meta-analysis: (1) information on the evaluation of *MFTHR Ala222Val* polymorphism and BC susceptibility; (2)Only the cohort and case-control studies were considered;(3) sufficient genotype data were presented to calculate the OR with 95% CI. Major reasons for exclusion of studies were: (1) none-case--control studies; (2) reviews and duplication of the previous publication; (3) control population including malignant tumor patients; (4) no usable data reported.

Data extraction
---------------

Two investigators reviewed and extracted information from all eligible publications independently, according to the inclusion and exclusion criteria listed above. An agreement was reached by discussion between the two reviewers whenever there was a conflict. The following items were collected from each study: first author's surname, year of publication, ethnicity, total number of cases and controls with Ala/Ala, Ala/Val, and Val/Val genotypes, respectively. Different descents were categorized as Caucasians, Asians, and Mixed populations which included more than one ethnic descent. For case--control studies, data were extracted separately for each group whenever possible.

Statistical analysis
--------------------

The strength of the association between *MFHTR Ala222Val* polymorphism and BC risk was measured by ORs, whereas a sense of the precision of the estimate was given by 95% Cls. The significance of the summary OR was determined with a Z-test. We first examined *MFHTR Ala222Val* genotypes using co-dominant model (homogeneous co-dominant model: Ala/Ala vs Val/Val, heterogeneous co-dominant model: Ala/Val vs Val/Val), recessive (Ala/Ala vs Ala/Val + Val/Val), and dominant (Ala/Ala + Ala/Val vs Val/Val) genetic models. Then, the relationship between the allele and susceptibility to BC was examined (addictive model: Ala allele vs Val allele). Stratified analyses were also performed by ethnicities. A chi-square-based Q-statistic test and an *I*^*2*^-test test were both performed to evaluate the between-study heterogeneity of the studies.

Two models including the fixed-effects model and the random-effects model of meta-analysis were applied for dichotomous outcomes. The fixed-effects model assumes that studies are sampled from populations with the same effect size, making an adjustment to the study weights according to the in-study variance. The random-effects model assumes that studies are taken from populations with varying effect sizes, calculating the study weights both from in-study and between-study variances, considering the extent of variation, or heterogeneity. A P-value ≥0.10 for the Q-test indicated lack of heterogeneity among the studies, and so the summary OR estimate of each study was calculated by the fixed-effects modelm \[[@B6]\]. Otherwise, the random-effects model (DerSimonian and Laird method) was used \[[@B7]\]. *I*^*2*^ statistic can be used to quantify heterogeneity irrespective of the number of studies. The significance of the pooled OR was determined by the Z-test and P\<0.05 was considered as statistically significant. Subgroup analyses were performed by ethnicity to explore the reasons of heterogeneity. Sensitivity analyses were performed to assess the stability of the results. To investigate whether publication bias might affect the validity of the estimates, funnel plot were constructed. An asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of OR. The significance of the intercept was determined by the t-test suggested by Egger (P\<0.05 was considered representative of statistically significant publication bias). All statistical tests were performed with Stata (Version 12.0, Stata Corporation, College Station, TX), using two-sided P-values.

Results
=======

Eligible studies
----------------

51 eligible studies on *MTHFR Ala222Val* genotypes and colorectal cancer were identified through literature search and selection based on the inclusion and exclusion criteria \[[@B8]-[@B58]\]. The publishing year of the studies was from 2002 to 2012. There were 25 studies of Caucasian, 19 studies of Asians and 7 studies of Mixed populations. In total, 20,907 BC cases and 23,905 controls were included in the meta-analysis. The selected study characteristics were summarized in Table [1](#T1){ref-type="table"}.

###### 

**The main characteristics of these studies and the distribution of MTHFR*Ala222Val*genotypes and alleles among cases and controls**

  **First author \[Inference\]**     **Year**   **Ethnicity**           **Cases**                **Controls**         ***HWE***
  ---------------------------------- ---------- --------------- ------ ----------- ----- ------ -------------- ----- -----------
  Sharp \[[@B8]\]                    2002       Caucasian         30       19        5     25         21        11      0.103
  Campbell \[[@B9]\]                 2002       Caucasian        140       162      33    118         92        23      0.420
  Semenza \[[@B10]\]                 2003       Caucasian         42       58        5    112        111        24      0.643
  Langsenlehner \[[@B11]\]           2003       Caucasian        208       222      64    215        215        65      0.333
  Ergul \[[@B12]\]                   2003       Caucasian         60       41       17     94         87        12      0.164
  Shrubsole \[[@B13]\]               2004       Asian            374       555      183   387        577        196     0.442
  Fo¨rsti \[[@B14]\]                 2004       Caucasian        134       81        8    181        104        13      0.689
  Lee \[[@B15]\]                     2004       Asian             58       96       32     50         80        17      0.076
  Grieu \[[@B16]\]                   2004       Caucasian        166       141      27    242        259        50      0.100
  Lin \[[@B17]\]                     2004       Asian             43       38        7    173        145        24      0.389
  Qi \[[@B18]\]                      2004       Asian             42       104      71     59        105        54      0.593
  Chen \[[@B19]\]                    2005       Mixed            398       476      189   440        509        155     0.689
  Kalemi \[[@B20]\]                  2005       Caucasian         19       16        7     23         20         8      0.313
  Deligezer \[[@B21]\]               2005       Caucasian         98       68       23    128         83        12      0.759
  Justenhoven \[[@B22]\]             2005       Caucasian        249       247      61    261        279        93      0.193
  Chou \[[@B23]\]                    2006       Asian             73       51       18    132        120        33      0.475
  Kalyankumar \[[@B24]\]             2006       Caucasian         45       37        6     61         31         3      0.693
  Xu \[[@B25]\]                      2007       Mixed            398       476      189   440        509        155     0.689
  Hekim \[[@B26]\]                   2007       Caucasian         22       16        2     38         26         4      0.872
  Macis \[[@B27]\]                   2007       Caucasian         14       20       12     28         41        11      0.511
  Yu \[[@B28]\]                      2007       Asian             56       54        9    225        170        25      0.336
  Reljic \[[@B29]\]                  2007       Caucasian         40       44        9     27         34         4      0.114
  Inoue \[[@B30]\]                   2008       Asian            239       120      21    393        226        43      0.178
  Kotsopoulos \[[@B31]\]             2008       Caucasian        383       421      140   252        341        87      0.087
  Suzuki \[[@B32]\]                  2008       Asian            150       220      84    338        425        146     0.522
  Cheng \[[@B33]\]                   2008       Asian            185       133      31    268        221        41      0.624
  Langsenlehner \[[@B34]\]           2008       Caucasian         51       43       11     40         48        17      0.685
  Ericson \[[@B35]\]                 2009       Caucasian        255       235      50    531        452        91      0.707
  Gao \[[@B36]\]                     2009       Asian            202       305      117   235        301        88      0.592
  Ma \[[@B37]\]                      2009       Asian            124       183      81    115        188        84      0.663
  Platek \[[@B38]\]                  2009       Mixed            429       446      119   788        795        219     0.398
  Henrı′quez-Herna′ndez \[[@B39]\]   2009       Caucasian         52       65       18    107        138        47      0.823
  Cam \[[@B40]\]                     2009       Caucasian         48       49       13     47         42         6      0.398
  Maruti \[[@B41]\]                  2009       Mixed            133       139      46    301        284        62      0.672
  Ma \[[@B42]\]                      2009       Mixed            225       188      45    222        187        49      0.309
  Li \[[@B43]\]                      2009       Asian             38       17       10     90         50         3      0.187
  Yuan \[[@B44]\]                    2009       Asian             16       35       29     32         35        13      0.516
  Jin \[[@B45]\]                     2009       Asian             18       20        3     49         41        10      0.742
  Bentley \[[@B46]\]                 2010       Caucasian        346       402      191   429        529        205     0.060
  Alshatwi \[[@B47]\]                2010       Asian             34       50       16     36         49        15      0.800
  Sangrajrang \[[@B48]\]             2010       Asian            410       144       9    366        110        11      0.427
  Weiner \[[@B49]\]                  2010       Caucasian        399       364      74    386        326        66      0.808
  Prasad \[[@B50]\]                  2011       Asian            124        5        1    116         8          1      0.062
  Batschauer \[[@B51]\]              2011       Caucasian         27       34        7     42         34         9      0.593
  Mohammad \[[@B52]\]                2011       Asian            168       53        1    198         37         0      0.190
  Naushad \[[@B53]\]                 2011       Asian            185       56        3    205         39         0      0.175
  Cerne \[[@B54]\]                   2011       Caucasian        222       238      62    108        124        37      0.882
  Akram \[[@B55]\]                   2012       Caucasian         65       25       20     55         45        10      0.855
  Barbosa \[[@B56]\]                 2012       Mixed             76       83       17     87         70        19      0.389
  Lajin \[[@B57]\]                   2012       Caucasian         44       52       23     65         48        13      0.359
  Jakubowska \[[@B58]\]              2012       Mixed            2032     2166      580   1447       1481       422     0.156

*HWE* Hardy--Weinberg equilibrium.

Meta-analysis results
---------------------

Overall, there was statistically significant difference in BC risk between the patients with Ala/Ala genotype and those with Val/Val genotype (OR=0.870, 95%CI=0.789-0.958, P=0.005; Figure [1](#F1){ref-type="fig"}). Similarly, significant associations were also found in the recessive model comparison (OR=0.944, 95%CI=0.898-0.993, P=0.026; Table [2](#T2){ref-type="table"}) and dominant model comparison (OR=0.882, 95%CI=0.808-0.963, P=0.005; Table [2](#T2){ref-type="table"}). Moreover, we found significant association between *Ala222Val* polymorphism and BC when examining the contrast of Ala versus Val (OR=0.935, 95%CI=0.887-0.986, P=0.013; Figure [2](#F2){ref-type="fig"}). In the stratified analysis by ethnicity, there was significant association between *Ala222Val* polymorphism and BC risk for Ala/Ala vs Val/Val comparison (OR=0.787, 95%CI=0.645-0.961, P=0.019; Figure [3](#F3){ref-type="fig"}), recessive model comparison (OR=0.890, 95%CI=0.799-0.991, P=0.034; Table [2](#T2){ref-type="table"}), dominant model comparison (OR=0.826, 95%CI=0.703-0.972, P=0.021; Table [2](#T2){ref-type="table"}) and Ala allele versus Val allele comparison (OR=0.877, 95%CI=0.801-0.960, P=0.008; Figure [4](#F4){ref-type="fig"}) among Asian populations. For Caucasian and Mixed populations, there was no significant association between *Ala222Val* polymorphism and breast cancer risk (Table [2](#T2){ref-type="table"}).

![**Forest plot of overall breast cancer risk associated with the*MTHFR Ala222Val*polymorphism (Ala/Ala versus Val/Val).**](1746-1596-7-171-1){#F1}

###### 

Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis

  **Variables**     **No. of studies**                                                           **Ala/Ala vs Val/Val**                                                                  **Ala/Ala vs Ala/Val**                                       **Ala/Val vs Val/Val**        
  ----------------- -------------------- -------------------------------------------- --------------------------------------------- ------------------------------ -------------------- ------------------------ -------------- -------------------- ------------------------ -----------
  Total             51                                0.870(0.789 0.958)                                  0.001                               **0.005**             0.969(0.923 1.016)           0.206               0.191       0.895(0.821 0.976)           0.021            **0.012**
  Asian             19                                0.787(0.645 0.961)                                  0.017                               **0.019**             0.929(0.843 1.023)           0.212               0.132       0.865(0.753 0.993)           0.300            **0.039**
  Caucasian         25                                0.869(0.741 1.020)                                  0.040                                 0.319               1.004(0.921 1.095)           0.137               0.926       0.910(0.778 1.064)           0.031              0.238
  Mixed             7                                 0.925(0.793 1.079)                                  0.050                                 0.087               0.958(0.898 1.022)           0.946               0.191       0.912(0.778 1.068)           0.050              0.253
  **Variables**     **No. of studies**    **Ala/Val + Ala/Val vs Val/Va (dominant)**   **Ala/Ala vs Ala/Val + Val/Va (recessive)**   **Ala allele vs Val allele**                                                                                                             
  **OR (95% CI)**   **P**~**h**~                            **P**                                    **OR (95% CI)**                         **P**~**h**~                 **P**             **OR (95% CI)**       **P**~**h**~         **P**                                  
  Total             51                                0.882(0.808 0.963)                                  0.004                               **0.005**             0.944(0.898 0.993)           0.055             **0.026**     0.935(0.887 0.986)           0.000            **0.013**
  Asian             19                                0.826(0.703 0.972)                                  0.075                               **0.021**             0.890(0.799 0.991)           0.043             **0.034**     0.877(0.801 0.960)           0.003            **0.008**
  Caucasian         25                                0.916(0.790 1.063)                                  0.030                                 0.247               0.985(0.908 1.069)           0.141               0.720       0.883(0.805 0.968)           0.052              0.359
  Mixed             7                                 0.888(0.758 1.041)                                  0.029                                 0.144               0.946(0.890 1.006)           0.773             **0.076**     0.957(0.838 1.094)           0.000              0.523

P~h~: P value of Q-test for heterogeneity test.
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![**Forest plot of a meta-analysis of the association between the*MTHFR Ala222Val*polymorphism and breast cancer susceptibility in Asians (Ala/Ala versus Val/Val).**](1746-1596-7-171-3){#F3}

![**Forest plot of a meta-analysis of the association between the*MTHFR Ala222Val*polymorphism and breast cancer susceptibility in Asians (Ala-allele versus Ala-allele).**](1746-1596-7-171-4){#F4}

Sensitivity analysis
--------------------

In order to compare the difference and evaluate the sensitivity of the meta-analyses, we conducted one-way sensitivity analysis to evaluate the stability of the meta-analysis. The statistical significance of the results was not altered when any single study was omitted, confirming the stability of the results. Hence, results of the sensitivity analysis suggest that the data in this meta-analysis are relatively stable and credible.

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias. The shape of funnel plots did not reveal any evidence of obvious asymmetry in all comparison models, and the Egger's test was used to provide statistical evidence of funnel plot symmetry. The results of Begg's test did not show any evidence of publication bias.

Discussion
==========

Breast cancer is currently the most frequently occurring cancer and the leading causes of cancer-related death among women in the world. Single nucleotide polymorphism (SNP) is the most common form of human genetic variation, and may contribute to individual's susceptibility to cancer, however, the underlying molecular mechanism is unknown. Previous study suggested that some variants, especially those in the promoter regions of genes, may affect either the expression or activity levels of enzymes \[[@B59]-[@B61]\] and therefore may be mechanistically associated with cancer risk. Previous studies on the relationship between *MTHFR Ala222Val* polymorphisms and BC risk were contradictory. These inconsistent results are possibly because of a small effect of the polymorphism on BC risk or the relatively low statistical power of the published studies. Hence, the meta-analysis was needed to provide a quantitative approach for combining the results of various studies with the same topic, and for estimating and explaining their diversity.

Meta analysis has great power for elucidating genetic factors in cancer. On the bases of the character of cancer, the effect of one genetic component on the development of the disease can be easily masked by other genetic and environmental factors. A meta-analysis potentially investigates a large number of individuals and can estimate the effect of a genetic factor on the risk of the disease \[[@B62],[@B63]\]. The present study included data from 51 association studies that had investigated the relationship between the *MTHFR Ala222Val* polymorphism and BC.

This present meta-analysis, including 20,907 cases and 23,905 controls, concerned the *Ala222Val* polymorphism of *MTHFR* gene and BC risk. In the meta-analysis, we found that the variant genotypes of the *MTHFR Ala222Val* polymorphisms were significantly associated with BC risk. Simultaneously, the same results presented in stratified analysis by ethnicity. We found that the variant genotype of the *MTHFR Ala222Val* polymorphism, in Asian populations, was associated with significant increase in BC risk. Although the *MTHFR Ala222Val* polymorphism may be associated with DNA repair activity, no significant association of the variant genotype with BC risk was found in Caucasian and Mixed populations, suggesting the influence of the genetic variant may be masked by the presence of other as-yet unidentified causal genes involved in colorectal cancer.

Some limitations of this meta-analysis should be acknowledged. First, our result was based on unadjusted estimates, while a more precise analysis should be conducted adjusted by other factors like diet habit, smoking, drinking status, environmental factors and so on. Second, in the subgroup analyses by ethnicity, relatively limited study numbers to perform ethnic subgroup analysis of mixed populations. Moreover, there are no American and African-American descent populations. Thus, additional studies are warranted to evaluate the effect of this functional polymorphism on BC risk in different ethnicities, especially in American, African-American and Mixed populations. In addition, our analysis did not consider the possibility of gene-gene or SNP-SNP interactions or the possibility of linkage disequilibrium between polymorphisms.

Despite of some limitations, this meta-analysis provided evidence of the association between the *MTHFR Ala222Val* polymorphisms and BC risk, supporting the hypothesis that *MTHFR Ala222Val* polymorphism contributes to overall BC risk. In subgroup analysis, the same results were found in Asian populations. In order to verify our findings, well-designed studies including different ethnic groups with a careful matching between cases and controls should be considered in future association studies to confirm the results from our meta-analysis. Moreover, further evaluating the effect of gene-gene and gene-environment interactions on the *Ala222Val* polymorphism and BC risk are necessary.
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